Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma

Non-transferrin-bound iron (NTBI) is detectable in plasma of β-thalassemia patients with transfusional iron overload. This form of iron may cause oxidative tissue damage and increased iron uptake, into several vital organs. Removal of NTBI species is incomplete and transient using standard intermitt...

Full description

Saved in:
Bibliographic Details
Main Authors: S. Srichairatanakool, C. Thephinlap, C. Phisalaphong, J. B. Porter, S. Fucharoen
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34648819489&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/61371
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-61371
record_format dspace
spelling th-cmuir.6653943832-613712018-09-10T04:09:35Z Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma S. Srichairatanakool C. Thephinlap C. Phisalaphong J. B. Porter S. Fucharoen Pharmacology, Toxicology and Pharmaceutics Non-transferrin-bound iron (NTBI) is detectable in plasma of β-thalassemia patients with transfusional iron overload. This form of iron may cause oxidative tissue damage and increased iron uptake, into several vital organs. Removal of NTBI species is incomplete and transient using standard intermittent desferrioxamine (DFO) or deferiprone (DFP) monotherapy. Combinations of these or other chelators may improve the protection time from NTBI and increase removal of harmful NTBI species. Curcuminoids from Curcuma Ionga L. is a naturally occurring phytochemical which shows a wide range of pharmacological properties including anti-oxidative, anti-inflammatory, anti-cancer and iron-chelating activities. In this study, the curcuminoids was investigated for NTBI chelation in thalassemic plasma in vitro and for the potential to improve NTBI removal when used with other chelators. Curcumin bound Fe3+ to form a Fe3+-curcumin complex with a predominant absorption at 500 nm. The chemical binding of curcumin was dose- and time-dependent and more specific for Fe3+ than Fe2+. Using a HPLC-based NTBI assay without an aluminium blocking step, curcumin shuttled the iron from Fe3+-NTA complex, giving underestimated NTBI values. At equivalent concentrations DFO, DFP and curcumin decreased plasma NTBI with the order of DFP>DFO>curcumin. None of these chelators removed NTBI completely, but curcumin appeared to increase the rate of NTBI removal when added to DFP. It is proposed that the β-diketo moiety of curcumin participates in the NTBI chelation. © 2007 Bentham Science Publishers Ltd. 2018-09-10T04:09:35Z 2018-09-10T04:09:35Z 2007-09-01 Journal 15734064 2-s2.0-34648819489 10.2174/157340607781745447 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34648819489&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/61371
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Pharmacology, Toxicology and Pharmaceutics
spellingShingle Pharmacology, Toxicology and Pharmaceutics
S. Srichairatanakool
C. Thephinlap
C. Phisalaphong
J. B. Porter
S. Fucharoen
Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma
description Non-transferrin-bound iron (NTBI) is detectable in plasma of β-thalassemia patients with transfusional iron overload. This form of iron may cause oxidative tissue damage and increased iron uptake, into several vital organs. Removal of NTBI species is incomplete and transient using standard intermittent desferrioxamine (DFO) or deferiprone (DFP) monotherapy. Combinations of these or other chelators may improve the protection time from NTBI and increase removal of harmful NTBI species. Curcuminoids from Curcuma Ionga L. is a naturally occurring phytochemical which shows a wide range of pharmacological properties including anti-oxidative, anti-inflammatory, anti-cancer and iron-chelating activities. In this study, the curcuminoids was investigated for NTBI chelation in thalassemic plasma in vitro and for the potential to improve NTBI removal when used with other chelators. Curcumin bound Fe3+ to form a Fe3+-curcumin complex with a predominant absorption at 500 nm. The chemical binding of curcumin was dose- and time-dependent and more specific for Fe3+ than Fe2+. Using a HPLC-based NTBI assay without an aluminium blocking step, curcumin shuttled the iron from Fe3+-NTA complex, giving underestimated NTBI values. At equivalent concentrations DFO, DFP and curcumin decreased plasma NTBI with the order of DFP>DFO>curcumin. None of these chelators removed NTBI completely, but curcumin appeared to increase the rate of NTBI removal when added to DFP. It is proposed that the β-diketo moiety of curcumin participates in the NTBI chelation. © 2007 Bentham Science Publishers Ltd.
format Journal
author S. Srichairatanakool
C. Thephinlap
C. Phisalaphong
J. B. Porter
S. Fucharoen
author_facet S. Srichairatanakool
C. Thephinlap
C. Phisalaphong
J. B. Porter
S. Fucharoen
author_sort S. Srichairatanakool
title Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma
title_short Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma
title_full Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma
title_fullStr Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma
title_full_unstemmed Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma
title_sort curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34648819489&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/61371
_version_ 1681425608185217024